JP2007532578A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532578A5
JP2007532578A5 JP2007507570A JP2007507570A JP2007532578A5 JP 2007532578 A5 JP2007532578 A5 JP 2007532578A5 JP 2007507570 A JP2007507570 A JP 2007507570A JP 2007507570 A JP2007507570 A JP 2007507570A JP 2007532578 A5 JP2007532578 A5 JP 2007532578A5
Authority
JP
Japan
Prior art keywords
vol
aminopyridine
spinal cord
journal
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007507570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532578A (ja
JP5736100B2 (ja
Filing date
Publication date
Priority claimed from US11/102,559 external-priority patent/US8354437B2/en
Application filed filed Critical
Publication of JP2007532578A publication Critical patent/JP2007532578A/ja
Publication of JP2007532578A5 publication Critical patent/JP2007532578A5/ja
Application granted granted Critical
Publication of JP5736100B2 publication Critical patent/JP5736100B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007507570A 2004-04-09 2005-04-11 徐放性アミノピリジン組成物の使用方法 Expired - Lifetime JP5736100B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US60/560,894 2004-04-09
US11/102,559 2005-04-08
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions
PCT/US2005/012427 WO2005099701A2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012100498A Division JP2012188427A (ja) 2004-04-09 2012-04-25 徐放性アミノピリジン組成物の使用方法
JP2014259950A Division JP5914626B2 (ja) 2004-04-09 2014-12-24 徐放性アミノピリジン組成物の使用方法

Publications (3)

Publication Number Publication Date
JP2007532578A JP2007532578A (ja) 2007-11-15
JP2007532578A5 true JP2007532578A5 (https=) 2008-05-29
JP5736100B2 JP5736100B2 (ja) 2015-06-17

Family

ID=35061389

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007507570A Expired - Lifetime JP5736100B2 (ja) 2004-04-09 2005-04-11 徐放性アミノピリジン組成物の使用方法
JP2012100498A Pending JP2012188427A (ja) 2004-04-09 2012-04-25 徐放性アミノピリジン組成物の使用方法
JP2014259950A Expired - Fee Related JP5914626B2 (ja) 2004-04-09 2014-12-24 徐放性アミノピリジン組成物の使用方法
JP2015114746A Withdrawn JP2015157861A (ja) 2004-04-09 2015-06-05 徐放性アミノピリジン組成物の使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012100498A Pending JP2012188427A (ja) 2004-04-09 2012-04-25 徐放性アミノピリジン組成物の使用方法
JP2014259950A Expired - Fee Related JP5914626B2 (ja) 2004-04-09 2014-12-24 徐放性アミノピリジン組成物の使用方法
JP2015114746A Withdrawn JP2015157861A (ja) 2004-04-09 2015-06-05 徐放性アミノピリジン組成物の使用方法

Country Status (21)

Country Link
US (13) US8354437B2 (https=)
EP (5) EP1732548B2 (https=)
JP (4) JP5736100B2 (https=)
AT (1) ATE511841T1 (https=)
AU (1) AU2005232732B2 (https=)
CA (2) CA2562277C (https=)
CY (4) CY1111754T1 (https=)
DK (2) DK1732548T4 (https=)
ES (2) ES2746354T3 (https=)
FI (2) FI1732548T4 (https=)
FR (1) FR13C0033I2 (https=)
HR (2) HRP20110497T4 (https=)
HU (1) HUE046320T2 (https=)
LU (2) LU91933I2 (https=)
ME (2) ME01836B (https=)
MX (3) MXPA06011648A (https=)
PL (2) PL1732548T5 (https=)
PT (2) PT2377536E (https=)
RS (2) RS53371B2 (https=)
SI (2) SI1732548T2 (https=)
WO (1) WO2005099701A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
AU2009291781A1 (en) * 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
AU2010213663A1 (en) * 2009-02-11 2011-09-29 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CA2825810A1 (en) 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of 4-aminopyridine to treat cerebral palsy
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
CA2864340A1 (en) 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
WO2014151752A1 (en) * 2013-03-15 2014-09-25 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
EP2986292A1 (en) 2013-04-15 2016-02-24 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
SG10201907291QA (en) 2015-02-08 2019-09-27 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CA3059180C (en) 2017-04-06 2023-10-17 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
TR2024006607A1 (tr) * 2024-05-28 2025-12-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The prolonged-release tablet comprising fampridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (https=) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
AU2004260702A1 (en) 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2006130726A2 (en) 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
ES2746121T3 (es) 2005-09-23 2020-03-04 Acorda Therapeutics Inc Método, aparato y software para la identificación de respondedores en un entorno clínico
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
AU2009291781A1 (en) 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
AU2010213663A1 (en) 2009-02-11 2011-09-29 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Similar Documents

Publication Publication Date Title
JP2007532578A5 (https=)
Krarup-Hansen et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies
Hayes et al. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury
Cha et al. Motor cortex stimulation activates the incertothalamic pathway in an animal model of spinal cord injury
Oaklander Common neuropathic itch syndromes
IL291791A (en) Methods for treating sleep timing disorders
Frost et al. Output properties of the cortical hindlimb motor area in spinal cord-injured rats
Unda et al. Beneficial effects of fish oil enriched in omega-3 fatty acids on the development and maintenance of neuropathic pain
KR100301415B1 (ko) 신경병치료에있어서4-아미노피리딘의사용
Zoetmulder et al. Sensorimotor gating deficits in multiple system atrophy: comparison with Parkinson's disease and idiopathic REM sleep behavior disorder
Stacheneder et al. Effects of transcranial direct current stimulation (t-DCS) of the cerebellum on pain perception and endogenous pain modulation: a randomized, monocentric, double-blind, sham-controlled crossover study
Elam et al. Does sympathetic nerve discharge affect the firing of polymodal C-fibre afferents in humans?
Chu et al. Effect of antispastic drugs on motor reflexes and voluntary muscle contraction in incomplete spinal cord injury
McLeod H reflex studies in patients with cerebellar disorders
Fisher Electrophysiological appraisal of relative segmental motoneurone pool excitability in flexor and extensor.
Bradley Critical review of gangliosides and thyrotropin‐releasing hormone in peripheral neuromuscular diseases
Mango et al. PDGF modulates synaptic excitability and short-latency afferent inhibition in multiple sclerosis
Sullivan et al. Levetiracetam for the treatment of generalized dystonia
Nukada et al. Disulfiram neuropathy: a morphometric study of sural nerve
Yang et al. Effects of blocking mGluR5 on primate dorsolateral prefrontal cortical neuronal firing and working memory performance
Kotchoubey et al. Event-related brain potentials in a patient with akinetic mutism
Sulaxane et al. Impact of height on sensory nerve conduction
Omer et al. Psychological impact of COVID-19 pandemic on medical students in Sudan, 2020
Lee et al. Isolated continuous rhythmic involuntary tongue movements following a pontine infarct
Baker III et al. Surgical treatment of propriospinal myoclonus: a case report